As such, silencing of Perk increased the therapeutic efficacy of treatments based on the depletion of amino acids in T cell leukemia [60], and sensitized chronic myeloid leukemia (CML) cells to the apoptosis induced by the BCR/ABL inhibitor, imatinib mesylate [61]. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.